Intellia Therapeutics is hoping to transform the future of medicine with its gene-editing technology, which its CEO likened to a pair of scissors.
"Add a ZIP code to the scissors and direct it to specific regions of your human genome to make edits, very similar to Microsoft Word where you are fixing a word that may have been misspelled," Nessan Bermingham said in an interview with CNBC's "Closing Bell" on Thursday.
Right now, any genetic disease is on the table. The technology can repair a mutation or modification within the DNA or insert a fragment of DNA to allow the company to generate a therapeutic protein for a specific disease, he said.
"We are now actually starting to better understand application and the breadth of the application of the technology today."